1541243-61-1Relevant articles and documents
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons
Belema, Makonen,Nguyen, Van N.,Romine, Jeffrey L.,St. Laurent, Denis R.,Lopez, Omar D.,Goodrich, Jason T.,Nower, Peter T.,O'Boyle, Donald R.,Lemm, Julie A.,Fridell, Robert A.,Gao, Min,Fang, Hua,Krause, Rudolph G.,Wang, Ying-Kai,Oliver, A. Jayne,Good, Andrew C.,Knipe, Jay O.,Meanwell, Nicholas A.,Snyder, Lawrence B.
, p. 1995 - 2012 (2014/04/03)
A medicinal chemistry campaign that was conducted to address a potential genotoxic liability associated with an aniline-derived scaffold in a series of HCV NS5A inhibitors with dual GT-1a/-1b inhibitory activity is described. Anilides 3b and 3c were used
